KEROS THERAPEUTICS INC (KROS)

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...

(NASDAQ:KROS)

Keros Therapeutics reports Q4 GAAP EPS of -$1.34, beating expectations by $0.04, with revenue of $0.14M.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Commit To Buy Keros Therapeutics At $50, Earn 18.5% Annualized Using Options

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...

Keros Therapeutics prices upsized stock offering to raise $140 million

Keros Therapeutics (KROS) on Wednesday priced an underwritten public offering of 3.5 million shares of its common stock at $40.00 per share, for an expected gross proceeds of $140.0 million.

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...

Keros Therapeutics looks to raise $120M through public offering (NASDAQ:KROS)

Keros Therapeutics plans to raise $120M through a public offering of its common stock, with an option for underwriters to purchase additional shares.

Keros Therapeutics Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065...

Keros stock falls after mid-stage data for blood cancer drug

Keros Therapeutics (KROS) stocks fell 16% after updating data from two Phase 2 trials for its lead protein drug in rare forms of blood cancer. Read more here.

Monday Sector Laggards: Drugs, Biotechnology Stocks

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical...

Commit To Purchase Keros Therapeutics At $20, Earn 12.9% Annualized Using Options

RSI Alert: Keros Therapeutics (KROS) Now Oversold

Relative Strength Alert For Keros Therapeutics

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Commit To Purchase Keros Therapeutics At $30, Earn 13% Annualized Using Options

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct...

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical...

Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023 (BBIO)

Acumen (ABOS), Establishment Labs (ESTA), Arcus (RCUS) and BridgeBio (BBIO) are four of BTIG's top picks for small and mid-cap healthcare stocks for 2H 2023. Read more here.

Oversold Conditions For Keros Therapeutics Inc KROS)

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

Notable Two Hundred Day Moving Average Cross - KROS

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology...

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

LEXINGTON, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused...

(NASDAQ:KROS)

Keros Therapeutics press release (KROS): Q1 GAAP EPS of -$1.26.Cash and cash equivalents as of March 31, 2023 was $351.4 million compared to $279.0 million as of December 31, 2022.

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

LEXINGTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical...

Why Shares of Keros Therapeutics Jumped This Week

The company appointed a new director and an analyst reiterated his position on the stock.